Thermo Fisher Scientific Introduces Orbitrap Ascend Tribrid

Designed to enable improved multiplexed proteomics and native protein characterization.

By: Kristin Brooks

Managing Editor, Contract Pharma

Thermo Fisher Scientific Inc. introduced a new mass spectrometry instrument and consumables that aim to enable biopharmaceutical and proteomics customers to drive scientific breakthroughs and solve analytical challenges. 
 
Designed to enable improved multiplexed proteomics and native protein characterization, the new Thermo Scientific Orbitrap Ascend Tribrid mass spectrometer offers new capabilities for multiplexed proteomics and native protein characterization. The mass spectrometer enables improved sample throughput, versatility, and ease-of-use—producing high quality data with simplicity, according to the company. More samples can be analyzed at lower concentrations, enabling faster, more sensitive analysis, and macromolecule experiments, that were not possible before, can now be achieved. The new Auto-Ready ion source for calibration maximizes convenience, allowing the user to spend more time on the results, and less time on instrument set-up, according to the company.
 
“Building upon the proven Tribrid architecture, our new mass spectrometer was designed for customers to address the most difficult analytical challenges,” said Rosy Lee, vice president and general manager, life sciences mass spectrometry, Thermo Fisher Scientific. “The instrument provides a single, versatile platform with single-cell sensitivity for proteomics and metabolomics, producing high-quality data with ease. This enables customers to tackle challenging analytes required to scale up their science.”
 
Joshua Coon, PhD Principal Investigator, Coon Laboratories, University of Wisconsin-Madison, said, “One feature on the Orbitrap Ascend Tribrid MS that is very exciting is its ability to route multiple ions. By moving the collision cell forward, the speed of the system is increased, allowing us to dig deeper into a sample and detect more, quicker.”
 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters